DBV Technologies

Profilo dell'azienda

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Descrizione disponibile in inglese.

Dati societari

Settore

Salute

Industria

Biotechnology

Paese

Francia

Sede

BAtiment IRO, 92320, Châtillon

Dipendenti

170

Quotazione

DBV · Euronext Paris

Valuta

EUR

ISIN

FR0010417345

Sito web

dbv-technologies.com